[Long-term efficacy and safety of pregabalin in patients with postherpetic
neuralgia: results of a 52-week, open-label, flexible-dose study]. [Article in Japanese]
Author(s): Ogawa S, Suzuki M, Arakawa A, Yoshiyama T, Suzuki M.
Affiliation(s): Surugadai Nihon University Hospital/Nihon University School of Medicine, Tokyo
Publication date & source: 2010, Masui. , 59(8):961-70
BACKGROUND: The efficacy of pregabalin was demonstrated in a randomized
double-blind placebo-controlled 13-week trial in 371 Japanese patients with
postherpetic neuralgia (PHN). In this study, we evaluated the long-term efficacy
and safety of pregabalin for relief of PHN.
METHODS: 126 patients were enrolled from the preceding double-blind study into
the 52-week open-label study. Patients were given pregabalin 150 to 600 mg x
day(-1). Pain intensity was measured using the Short-Form McGill Pain
Questionnaire (SF-MPQ: total score, visual analogue scale and present pain
RESULTS: The efficacy parameter SF-MPQ showed a decrease over the treatment-term.
The changes of visual analogue scale and present pain intensity at the endpoint
were -28.3 mm and -1.1 score, respectively. The commonly reported adverse events
were dizziness, somnolence, peripheral edema and weight gain, and most of them
were mild to moderate in intensity. No new adverse events were observed due to
long-term pregabalin administration.
CONCLUSIONS: These results suggest that long-term treatment of pregabalin may be
beneficial in patients with PHN.